This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Research steps toward a compound that could prevent pregnancy if taken within six days after sexual intercourse were reported to the American Fertility Society.
John McL. Morris, MD, told the 22nd annual meeting in Chicago that studies began more than two years ago at Yale University on a compound which appears in animal experiments to fulfill requirements of non-toxicity, non-teratogenicity, and 100% effectiveness.
But he said the compound, which is a carboxylic acid derivative developed by Ortho Research Foundation of Raritan, NJ, and called ORF-3858, has not been approved by the US Food and Drug Administration for human use.
Limited initial tests with human volunteers, including some rape victims, were done therefore with diethylstilbestrol which, with other commercially available estrogens such as ethinyl estradiol, mestranol and estradiol, underwent evaluation by Yale investigators, Dr. Morris said. This was done because estrogenic properties had been noted in ORF-3858, which is not a
Post-Intercourse Contraceptive Tested. JAMA. 1966;196(7):41. doi:10.1001/jama.1966.03100200023010